Special Educational Needs: support in England
An overview of the current system of support for children and young people with special educational needs, and pressure on the system. Updated with new 2024-25 SEND incidence and EHC plan data

This Commons Library Debate Pack provides information for the debate, entitled "APPG report Impact of Health and Social Care Act on HIV treatment" and sponsored by Mike Freer, which will take place in Westminster Hall on Wednesday 29th March at 2.30pm, lasting for 90 minutes.
APPG report Impact of Health and Social Care Act on HIV treatment (4 MB , PDF)
This debate follows the publication by the All-Party Parliamentary Group on HIV and AIDS’ report, “The HIV Puzzle: Piecing together HIV care since the Health and Social Care Act” in November 2016. This report argued that since the implementation of the Health and Social Care Act 2012 there has been a ‘fragmentation’ of HIV and sexual health services. This is because of the split in commissioning responsibilities between NHS England, Clinical Commissioning Groups (CCGs) and local authorities. There has been particular uncertainty about who is responsible for commissioning Pre Exposure Prophylaxis (PrEP), medication used to prevent the contraction of HIV.
The APPG report made several recommendations to the Government, including:
1) That it clarify commissioning responsibility for HIV support services and protecting their budgets across the country.
2) That it encourage Public Health England to further integrate HIV and sexual health services.
3) And that it ensure that NHS England acknowledges its responsibility for commissioning PrEP.
APPG report Impact of Health and Social Care Act on HIV treatment (4 MB , PDF)
An overview of the current system of support for children and young people with special educational needs, and pressure on the system. Updated with new 2024-25 SEND incidence and EHC plan data
The Rare Cancers Bill 2024-2025 had its second reading on Friday 14 March 2025. It was considered in Public Bill Committee on 2 July 2025 and report stage is scheduled for 11 July 2025. This is a private members' bill.
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab